Endothelin Antagonism in ANCA Vasculitis

University of Edinburgh

Status: Completed

Conditions: Vasculitis

Treatments: Drug: BQ123; Drug: Placebo; Drug: BQ123/788

Study type: Interventional

Funder types: Other

Identifiers

NCT02062346

Bean ICRF clinical study

Details and patient eligibility

About

Patients with vasculitis commonly develop cardiovascular disease. The reasons for this are not clear and is not adequately treated with current drugs. It is thus understand the reasons why patients with vasculitis develop cardiovascular disease in order to develop new drugs to reduced this risk.

Endothelin is a chemical produced by blood vessels that contributes to the development of hypertension and cardiovascular disease Higher than normal levels of endothelin are seen in patients with vasculitis but how this contributes to cardiovascular disease in patients with vasculitis is not clear. By using drugs that block the effects of endothelin ('endothelin receptor antagonists') the investigators can hopefully reduce the risk of cardiovascular disease in patients with vasculitis. The purpose of the study is to ascertain if endothelin receptor antagonists improve blood vessel function in patients with vasculitis.

Full description

Vasculitis patients and healthy controls matched for age, sex will be enrolled into the study. Patients will attend for 4 study days >1 week apart, whereas controls will attend for single day. Circulating Mφ and other immune cells will be confirmed using FACS prior each study.

Study 1 Both patients and control will attend for visit 1: assessment of vascular function using forearm plethysmography as part of case control study.

Vasculitis patients will then attend for visits 2, 3 & 4 as part of randomised three way crossover study (randomised & infusions given in a double-blind method): comparison of the effects of selective ETA receptor antagonism (BQ123; 1000nmol/min for 15min iv), mixed ETA/B antagonism (BQ123/788; 1000 nmol/min & 300 nmol/min for 15 min), and placebo on systemic haemodynamics.

Enrollment: 64 patients

Sex: All

Ages: 18 to 100 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Male or female
• Age 18 years and over
• Body mass index ≤35
• Normal serum albumin

Exclusion criteria

• Subject with diabetes or current smoking or chronic kidney disease (eGFR <60ml/min)
• Subject with pre-existing cardiovascular disease
• Subject is below the age of legal consent, or is mentally or legally incapacitated
• History of multiple and/or severe allergic reactions to drugs (including study drugs)
• The subject has donated blood (450 ml) within the last 4 weeks
• Past or present drug or alcohol abuse including intravenous drug abuse at any time
• Participation in another clinical trial within 1 month
• Considered to be at high risk of HIV or hepatitis B
• Women of child-bearing potential (only women who are post-menopausal or surgically-sterilised will be included in the study)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

64 participants in 4 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

Saline placebo

Treatment:

Drug: Placebo

BQ123

Experimental group

Description:

Intravenous infusion of BQ123 1000nmol/min for 15min

Treatment:

Drug: BQ123

BQ123/788

Experimental group

Description:

Intravenous infusion of BQ123 1000nmol/min and BQ788 300nmol/min

Treatment:

Drug: BQ123/788

Assessment of forearm vascular function

No Intervention group

Description:

Response of forearm blood flow to endothelium-dependent and endothelium-independent vasodilators